Premium
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis SOLAPSO – Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society)
Author(s) -
Kogan Nora,
Raimondo Nélida,
Gusis Simon E.,
Izcovich Ariel,
Abarca Duran Jorge A.,
BarahonaTorres Lilia,
Blanco Orestes,
Quintana Gerardo B.,
Briones María C.,
Castro Carla,
Castro Vargas Evelyn G.,
Criniti Juan,
Diez de Medina Juan C.,
Franco Manuel,
Gómez Minerva,
Levrero Patricia,
Martínez López Jaime E.,
Valenzuela Fernando
Publication year - 2019
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.14471
Subject(s) - medicine , psoriasis , observational study , guideline , quality of life (healthcare) , clinical trial , psychological intervention , randomized controlled trial , adverse effect , systemic therapy , family medicine , latin americans , alternative medicine , medline , dermatology , surgery , nursing , pathology , cancer , linguistics , philosophy , breast cancer , political science , law
This Clinical Practice Guideline on the systemic treatment of Psoriasis includes the recommendations elaborated by a panel of experts from the Latin American Psoriasis Society SOLAPSO , who assessed the quality of the available evidence using the GRADE system and the PICO process to guide the literature search. To answer each question, the experts discussed the results of randomized controlled trials, observational studies and metanalysis evaluating the interventions identified (non‐biologics, biologics and phototherapy) in different populations of patients with moderate to severe plaque‐psoriasis, which was summarized in Tables ad‐hoc. The main end‐points considered to assess efficacy were PASI 50, 75, 90 and 100, PGA 0‐1 and significant improvement of health‐related quality of life. Specific adverse events, either severe or leading to treatment interruption, were also evaluated. The 31 recommendations included in this CPG follow the structure proposed by GRADE : direction (for or against) and strength (strong or weak). The goal of this CPG is to improve the management of patients with psoriasis by recommending interventions of proved benefit and providing a reference standard for the treating physician. Adhering to the contents of this CPG does not guarantee therapeutic success. The final decision on the specific treatment is the responsibility of the physician based on the individual circumstances and considering the values, the preferences and the opinions of the patient or caregivers.